Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
|Articles|February 1, 2007
Couples better at detection
New York - Men and women at high risk of developing melanoma, and who underwent skin self-exam training with a live-in partner, were more likely to perform the exams than those trained alone, according to a study published in Archives of Dermatology.
Advertisement
New York - Men and women at high risk of developing melanoma, and who underwent skin self-exam training with a live-in partner, were more likely to perform the exams than those trained alone, according to a study published in Archives of Dermatology.
Researchers found that people trained to perform skin self-exams also seek treatment at an earlier stage and are less likely to die from the disease, Reuters reports.
Advertisement
Related to this article
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
4
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
5